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Abstract.
Background: The search for a biomarker of Alzheimer’s disease (AD) pathology (amyloid- (A) and tau) is ongoing,
with the best markers currently being measurements of A and tau in cerebrospinal fluid (CSF) and via positron emission
tomography (PET) scanning. These methods are relatively invasive, costly, and often have high screening failure rates.
Consequently, research is aiming to elucidate blood biomarkers of A and tau.
Objective: This study aims to investigate a case/control polygenic risk score (PGRS) as a marker of tau and investigate blood
markers of a combined A and tau outcome for the first time. A sub-study also considers plasma tau as markers of A and
tau pathology in CSF.
Methods: We used data from the EDAR*, DESCRIPA**, and Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohorts
in a logistic regression analysis to investigate blood markers of A and tau in CSF. In particular, we investigated the extent to
which a case/control PGRS is predictive of CSF tau, CSF amyloid, and a combined amyloid and tau outcome. The predictive
ability of models was compared to that of age, gender, and APOE genotype (‘basic model’).
Results: In EDAR and DESCRIPA test data, inclusion of a case/control PGRS was no more predictive of A, and a combined
A and tau endpoint than the basic models (accuracies of 66.0%, and 73.3% respectively). The tau model saw a small increase
in accuracy compared to basic models (59.6%). ADNI 2 test data also showed a slight increase in accuracy for the A model
when compared to the basic models (61.4%).
Conclusion: We see some evidence that a case/control PGRS is marginally more predictive of A and tau pathology than
the basic models. The search for predictive factors of A and tau pathologies, above and beyond demographic information,
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apply/ADNI Acknowledgement List. pdf.
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is still ongoing. Better understanding of AD risk alleles, development of more sensitive assays, and studies of larger sample
size are three avenues that may provide such factors. However, the clinical utility of possible predictors of brain A and tau
pathologies must also be investigated.
*‘Beta amyloid oligomers in the early diagnosis of AD and as marker for treatment response’
**‘Development of screening guidelines and criteria for pre-dementia Alzheimer’s disease’
Keywords: Alzheimer’s disease, biomarker, blood, multi-modal, polygenic risk score, tau
INTRODUCTION
The hallmark pathologies of Alzheimer’s disease
(AD) are amyloid- (A) plaques and phosphory-
lated tau tangles in the brain. Although diagnostic
criteria for AD focus on pathological evidence of A,
tau levels in cerebrospinal fluid (CSF) are also con-
sidered [1]. Jack et al. provide a theoretical model
for the progression of AD based on existing evidence
that is consistent with the popular amyloid cascade
hypothesis [2, 3]. This hypothesis states that the build
up of tau is triggered by increasing levels of A in
the brain.
The search for a biomarker of AD pathologies (tau
and A) is ongoing with the best markers currently
being measurements of tau and A in the CSF and
via positron emission tomography (PET) scanning.
These methods are relatively invasive and often have
high screening failure rates meaning a high propor-
tion of individuals that are scanned have low levels
of these pathologies. Additionally, PET scanning in
particular is an expensive procedure costing around
$3,000 per scan [4]. There are only approximately
2,380 (http://www.imvinfo.com, August 2016) PET
scanners in the United States meaning access to facil-
ities is limited [5]. The lumbar puncture needed to
access CSF is also considered a high-risk proce-
dure in many western countries [6]. To address these
shortcomings, research is aiming to elucidate blood
biomarkers of AD pathologies (A and tau) [7]. One
motivation for discovering a blood-based biomarker
of AD pathology comes from clinical trial recruit-
ment. For example, when recruiting into a trial of an
anti-amyloid therapeutic, a blood-based biomarker of
A could act as a filtering step to identify individu-
als with abnormal levels of A before performing a
confirmatory PET scan or lumbar puncture. As such
a test is likely to be cost-effective, we could reduce
the cost of screening while also reducing the number
of individuals subject to the invasive lumbar punc-
ture and PET scanning procedures. So far, research
into a blood marker has largely focused on A brain
burden, rather than tau pathology. However, some
studies have investigated genetic markers of tau [8].
This study aims to further this research by investigat-
ing markers of a combined A and tau outcome for
the first time.
Genome wide association studies (GWAS) of AD
to date have identified over 20 risk loci explaining
approximately 16–33% of genetic variability in the
disease [9–13]. Compared to the predicted heritabil-
ity of 50–70%, this is fairly low [13–15]. Modern
technologies including next generation sequencing
and the development of high coverage, exome chips
are beginning to address this issue of missing her-
itability. Meanwhile polygenic risk scores (PGRS)
are aiming to combine genetic risk from variants of
lower effect size [16]. To date, PGRS in AD have
only been trained on case/control endpoints as GWAS
studies of pathological outcomes are relatively small
(for example, N = 1,269 [17]). Studies have shown
case/control PGRS are associated with AD-related
phenotypes but few have investigated their predictive
ability in test data [18, 19]. When we studied the pre-
dictive ability of a PGRS for A burden, we saw that
the case/control PGRS used was no more predictive
than demographics (age, gender) and APOE geno-
type alone (Voyle et al., in submission). However,
we hypothesize in the current study that the PGRS
may be more predictive of a combined A and tau
outcome; a more ‘AD-like’ phenotype.
This study aims to investigate the predictive ability
of a case/control PGRS on CSF A and tau. A sub-
study will also consider plasma tau as a predictor.
We use individuals from the Alzheimer’s Dis-
ease Neuroimaging Initiative (ADNI), EDAR, and
DESCRIPA studies to investigate these associations
and compare all models to those of demograph-
ics (age, gender) and APOE genotype [20, 21]. We
hypothesize that blood markers of AD will perform
better when predicting a combined pathology (tau and
A) endpoint over tau and A individually. The com-
bined endpoint should be more representative of an
‘AD-like’ phenotype.
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MATERIALS AND METHODS
Cohorts
EDAR was a prospective, longitudinal study which
aimed to examine and evaluate biomarkers of early
AD and treatment response [21]. In particular, the
study focused on A oligomers and the effect of
genetic variants on these oligomers. For more infor-
mation see http://www.edarstudy.eu. Our access to
samples and clinical and phenotypic information
from the EDAR study was enabled by the European
Medical Information Framework and has been previ-
ously described (Voyle et al. in submission).
DESCRIPA was also a prospective, multi-center
study. It was coordinated by the European AD
Consortium and focused on collecting data from
non-demented subjects with the aim of developing
screening guidelines and clinical criteria for AD.
Further details of this study can be found in Visser
et al. [20].
ADNI is a longitudinal cohort study aiming
to validate the use of biomarkers in AD clinical
trials and diagnosis. Data used in the prepara-
tion of this article were obtained from the ADNI
database (http://adni.loni.usc.edu). The ADNI study
was launched in 2003 as a public-private partnership,
led by Principal Investigator Michael W. Weiner, MD.
The primary goal of ADNI has been to test whether
biological markers and clinical and neuropsycho-
logical assessment can be combined to measure the
progression of mild cognitive impairment (MCI) and
AD. ADNI was approved by the institutional review
boards of all participating institutions, and written
informed consent was obtained for all participants.
This study uses data from ADNI 1 and the ADNI 2
and ADNI GO sub-groups, referred to as ADNI 2
from here onwards.
Genetics
Samples from EDAR and DESCRIPA were geno-
typed on the Illumina HumanOmniExpressExome-
8v1.2 BeadChip (N = 336) [22]. The data has
previously been reported on by Voyle et al. (in
submission). The HumanOmniExpressExome Bead-
Chip has been optimized to tag SNPs that capture a
large amount of common genetic variation. In total,
the chip contains 960,919 markers of which over
273,000 correspond to functional exomic markers.
ADNI 1 samples were run on the Human610-Quad
BeadChip (N = 818), which has since been discontin-
ued. The chip provides coverage of 924,000 randomly
selected SNPs. ADNI 2 and ADNI GO samples were
run on the Illumina HumanOmniExpress BeadChip
(N = 432). This chip is similar to the HumanOm-
niExpressExome BeadChip used in the EDAR and
DESCRIPA studies but does not include the exomic
markers. In total, the chip contains 713,599 mark-
ers. Details of the genotyping protocols followed in
ADNI are given elsewhere [23]. Details of the data
processing are briefly outlined below.
The cohorts were subject to quality control and
imputation separately, as described in Coleman et al.
[24]. In short, the data was filtered to ensure a minor
allele frequency of greater than 5% for all SNPs before
removal of rare variants and subjects with high lev-
els of missing data. SNPs that differed significantly
(p < 0.00001) from the Hardy-Weinberg equilibrium
were removed. The data was pruned for SNPs in
linkage disequilibrium and for genetically similar
individuals. Finally, the data was imputed using ref-
erence files from the 1000 Genomes Project [25].
CSF Measurements
This study focuses on total tau (tTau) and A
measurements in CSF. The analysis considered three
endpoints: dichotomized A, dichotomized tTau, and
a binary representation of overall pathology. For the
latter analysis, referred to as total CSF burden, each
cohort was reduced to those individuals with normal
A and normal tTau, or abnormal A and abnormal
tTau. The distributions of tTau and A were similar
between cohorts in terms of shape but not in absolute
value. Consequently, this work focused solely on a
dichotomized outcome.
EDAR
Details of CSF collection and analysis can be found
at http://www.edarstudy.eu. In brief, CSF measure-
ments were collected using the Alzbio3 Luminex
assay in one batch at the end of the study. CSF A
and tTau measurements were dichotomized at the
previously published thresholds of 389 pg/ml and
98 pg/ml, respectively.
DESCRIPA
Details of CSF measurements in DESCRIPA have
been described elsewhere [22]. In brief, CSF mea-
surements were analyzed in one laboratory and
collected using single-parameter ELISA kits
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(Innogenetics, Ghent, Belgium). CSF A and tTau
samples were dichotomized using the previously
published thresholds of 550 pg/ml and 375 pg/ml,
respectively.
ADNI
For ADNI, datasets used to extract CSF measures
of A and tau were chosen to maximize sample size.
The dataset ‘UPENNBIOMK2’ was used for ADNI 1
and ‘UPENNBIOMK6’ for ADNI 2 and ADNI GO.
Both datasets contain CSF measurements collected
using the xMAP Luminex platform and Innogenetics
immunoassay kits. The CSF measures of amyloid and
tTau were dichotomized at the previously published
thresholds (192 pg/ml and 93 pg/ml, respectively).
Plasma Tau (ADNI 1 only)
Plasma tau was investigated as a potential blood
biomarker of A and tau in a sub-study. ADNI 1 was
the only cohort with such data available. Plasma tau
was analyzed by the Single Molecule Array (SIMOA)
technique and the Human total tau assay using a com-
bination of monoclonal antibodies. Samples with a
plasma tau concentration below the lower limit of
quantification (<1.0 pg/ml) were removed (N = 36).
Outliers, identified as values greater than 6 standard
deviations from the mean, were removed (N = 2) and
the data was subject to a natural logarithm transfor-
mation.
Statistical analysis
All statistical analysis was performed in R version
3.1.1 [26].
The three endpoints of interest (dichotomized amy-
loid, dichotomized tTau, and total CSF burden) were
modeled using logistic regression models covarying
for age, gender, and APOE genotype. An individuals
APOE genotype was coded as 1 if at least one4 allele
was present and 0 otherwise. Models were also built
using only the demographic variables age, gender,
and APOE genotype, for comparison. Throughout
this study these models are referred to as ‘basic
models’.
Two analyses were performed to study these three
endpoints of interest:
1. PGRS: Models were built in ADNI 1 data (A
and tau N = 363; Total CSF burden N = 244) and
tested in data from EDAR and DESCRIPA (A
and tau N = 250; Total CSF burden N = 135) and
Table 1
Sample sizes
PGRS analysis
Outcome ADNI 1 (N) EDAR and ADNI 2 (N)
DESCRIPA (N)
Dichotomized amyloid 363 250 44
or tTau
Total CSF burden 244 135 37
PGRS and plasma tau analysis
Outcome ADNI 1 (N)
Dichotomized amyloid 323
or tTau 323
Total CSF burden
ADNI 2 (A and tau N = 44; Total CSF burden
N = 37).
2. PGRS and plasma tau: Models were built
and tested in ADNI 1 using 5 fold cross-
validation (A and tau N = 323; Total CSF
burden N = 219).
The sample sizes of each dataset used in these
analyses are given in Table 1.
All models including a PGRS co-varied for
the first three genetic principal components to
account for population structure. The predictive
ability of each model was quantified using
accuracy, sensitivity, specificity and area under
the receiver operating characteristic (ROC) curve
[27–29].
PGRS
PGRS were created within each cohort using
PRSice [30]. Effect sizes from stage 1 of the Inter-
national Genomics of Alzheimer’s Project (IGAP)
case/control GWAS were used as the weights to
generate the risk score [9]. We used 0.5 as the p-
value threshold for inclusion in the PGRS. This
threshold showed the most significant association
with case/control diagnosis in the large IGAP PGRS
study [31]. The genetic region coding for APOE was
removed from all scores and included as a separate
covariate due to its strong influence. The PGRS was
standardized by subtracting the mean and dividing
by the standard deviation, per cohort. This aims to
account for the scores including different SNPs due to
availability on the different SNP chips. It is important
to note that APOE genotype is included as a covari-
ate in modeling and not in the PGRS. Therefore, the
PGRS is only exploring variation above and beyond
APOE. This is different to the focus of the IGAP
PGRS study which included APOE within the PGRS
[31]. We have chosen this approach to investigate
N. Voyle et al. / Genetic Risk as a Marker of Amyloid- and Tau Burden in Cerebrospinal Fluid 1421
Table 2
Cohort demographics – Dichotomized A
ADNI 1 (N = 363) ADNI 2 (N = 44) EDAR and DESCRIPA*
(N = 250)
Demographic Normal Abnormal p-value Normal Abnormal p-value Normal Abnormal p-value
CSF A CSF A CSF A CSF A CSF A CSF A 
(N = 112) (N = 251) (N = 27) (N = 17) (N = 99) (N = 151)
Median age [IQR] 74.4 [8.35] 75.3 [8.55] 0.825 67.8 [12.55] 75.2 [11.1] 0.049 66 [12] 69 [13] 0.136
Gender (%) 0.487 0.359 0.052
Female 36.6 40.6 51.9 35.3 38.4 51.7
Male 63.4 59.4 48.1 64.7 61.6 48.3
Median years in education [IQR] 16 [4.25] 16 [4] 0.748 16 [4] 16 [4] 0.825 11.5 [8] 10 [7] 0.133
Median MMSE [IQR] 29 [3] 26 [4] <0.001 29 [2] 27 [3] 0.058 27.5 [4] 26 [5] 0.009
Diagnosis (%) <0.001 0.247 0.001
Dementia 6.3 33.5 0 5.9 34.3 45.0
MCI 40.1 51.0 74.1 82.4 43.4 41.1
SCI 0 0 0 0 5.1 10.6
CTL 53.6 15.5 25.9 11.7 17.2 3.3
APOE status (%) <0.001 0.225 <0.001
0 85.7 33.5 66.7 47.1 74.7 38.4
1 14.3 66.5 33.3 52.9 25.3 61.6
Kruskal Wallis chi-squared was used to test between normal and abnormal groups for continuous demographic variables. Fishers exact
was used to test between normal and abnormal groups for categorical demographic variables. APOE status is 1 if an individual’s genotype
contains any 4 alleles, and 0 otherwise. IQR, Inter-quartile range; CSF, cerebrospinal fluid; MMSE, Mini-Mental State Exam; MCI, mild
cognitive impairment; SCI, subjective cognitive impairment; CTL, control. ∗One individual has missing diagnosis, 2 have missing education
information, and 3 have missing MMSE.
whether information from a SNP chip adds anything
above APOE. Furthermore, generally, APOE is not
well measured on SNP chips so APOE genotype is
determined by targeted genotyping.
The datasets used for model testing (EDAR and
DESCRIPA) were not included in the IGAP study.
Furthermore, although some samples from ADNI
were included in IGAP, the majority were only
included in the training, not testing, stages.
RESULTS
Cohort demographics
Table 2 shows demographics against normal and
abnormal CSF A while Table 3 is against CSF
tTau. Demographics for the sub-population used in
the total CSF burden analysis are given in Supple-
mentary Table 1. Demographics for the sub-group of
ADNI 1 individuals with plasma tau measurements
is given in Supplementary Table 2.
In ADNI 1 training data and EDAR/DESCRIPA
test data, there is a significant difference between
normal and abnormal A in MMSE, diagnosis, and
APOE genotype as we would expect. Similar asso-
ciations are also seen with dichotomized tTau. The
smaller sample size of the ADNI 2 test data (N = 44)
is likely to have driven the lack of association in this
group of individuals.
Data analysis
Genetic risk
The PGRS was not significant in any of the logis-
tic regression models (p-values of 0.995, 0.929,
and 0.796 for tTau, A, and total CSF burden
respectively). The inclusion of the PGRS marginally
improved the predictive ability of tTau models over
the basic models. The accuracy of the A model was
also marginally improved by inclusion of the PGRS
in ADNI 2 test data. The models of total CSF bur-
den had the highest accuracies (72% and 65%). See
Table 4 for full results.
Genetic risk and plasma tau
When modeling CSF tTau no model outperformed
the basic model at an accuracy of 66%. Similarly,
when modeling total CSF burden the inclusion of a
PGRS and plasma tau did not improve predictive abil-
ity above the basic model (77%). The only model to
see an improvement over the basic model was when
modeling A. Inclusion of plasma tau measurements
marginally improved accuracy from 71% to 74% and
the area under the ROC curve from 0.658 to 0.697.
See Table 5 for full results.
DISCUSSION
The aim of this study was to investigate blood
biomarkers that may be predictive of AD pathologies
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Table 3
Cohort demographic - Dichotomized total tau
ADNI 1 (N = 363) ADNI 2 (N = 44) EDAR and DESCRIPA*
(N = 250)
Demographic Normal Abnormal p-value Normal Abnormal p-value Normal Abnormal p-value
CSF tau CSF tau CSF tau CSF tau CSF tau CSF tau
(N = 203) (N = 160) (N = 30) (N = 14) (N = 150) (N = 100)
Median age [IQR] 75.2 [8] 74.45 [10] 0.642 67.85 [10.7] 76.75 [12.68] 0.051 66.55 [13] 70.5 [12] 0.032
Gender (%) 0.234 >0.999 0.094
Female 36.5 43.1 46.7 42.9 42.0 53.0
Male 63.5 56.9 53.3 57.1 58.0 47.0
Median years in education [IQR] 16 [4] 16 [5] 0.064 16 [4] 16 [4] 0.7 10 [6] 9 [8] 0.032
Median MMSE [IQR] 28 [3] 26 [4] <0.001 29 [1.75] 27 [3.75] 0.153 28 [4] 26 [4] <0.001
Diagnosis (%) <0.001 0.38 <0.001
Dementia 15.8 36.9 0 7.1 26.7 62.0
MCI 45.8 50.0 76.7 78.6 47.3 34.0
SCI 0 0 0 0 12.7 2.0
CTL 38.4 13.1 23.3 14.3 13.3 2.0
APOE status (%) <0.001 0.191 0.001
0 63.5 31.9 66.7 42.9 59.3 43.0
1 36.5 43.1 33.3 57.1 40.7 57.0
Kruskal Wallis chi-squared was used to test between normal and abnormal groups for continuous demographic variables. Fishers exact
was used to test between normal and abnormal groups for categorical demographic variables. APOE status is 1 if an individual’s genotype
contains any 4 alleles, and 0 otherwise. IQR, inter-quartile range; CSF, cerebrospinal fluid; MMSE, Mini-Mental State Exam; MCI, mild
cognitive impairment; SCI, subjective cognitive impairment; CTL, control. ∗One individual has missing diagnosis, 2 have missing education
information, and 3 have missing MMSE.
Table 4
PGRS: Test data results
Outcome Model Accuracy Sensitivity Specificity AUC ROC
EDAR and DESCRIPA
tTau Demographics only 0.584 0.570 0.593 0.625
A Demographics only 0.660 0.788 0.465 0.686
Total CSF burden Demographics only 0.733 0.750 0.716 0.801
tTau Demographics and PGRS 0.596 0.560 0.620 0.609
A Demographics and PGRS 0.616 0.768 0.384 0.692
Total CSF burden Demographics and PGRS 0.719 0.702 0.702 0.748
ADNI 2
tTau Demographics only 0.636 0.571 0.667 0.655
A Demographics only 0.546 0.765 0.407 0.527
Total CSF burden Demographics only 0.649 0.583 0.680 0.693
tTau Demographics and PGRS 0.659 0.571 0.700 0.671
A Demographics and PGRS 0.614 0.647 0.593 0.590
Total CSF burden Demographics and PGRS 0.649 0.583 0.680 0.683
AUC ROC, area under the receiver operating curve; PGRS, polygenic risk score.
(A and tau). We modeled levels of A and tau in
CSF using a PGRS and a sub-study considered mea-
surements of tau in blood plasma. We also studied a
total CSF burden endpoint for individuals with abnor-
mal tau and A, or normal tau and A. The results
shown here highlight that a case/control PGRS and
plasma tau do not substantially outperform demo-
graphics (age, gender) and APOE genotype. The
highest model accuracies were seen when modeling
the total CSF burden phenotype.
Several studies have focused on identification of
blood biomarkers of A [17, 32, 33]. However, few
have achieved successful replication. The hypothesis
tested in this study was that a combined tau and A
endpoint would be closer to an AD case/control phe-
notype and consequently easier to predict. This study
supports this hypothesis, although the improvements
in accuracy are minimal. Further, this accuracy of pre-
diction was achieved by the basic model and the two
blood biomarkers investigated, a case/control PGRS
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Table 5
PGRS and plasma tau: Five fold cross-validation results
Outcome Model Accuracy Sensitivity Specificity AUC ROC
tTau Demographics only 0.656 0.691 0.628 0.659
tTau Demographics and PGRS 0.638 0.665 0.617 0.641
tTau Demographics and plasma tau 0.650 0.587 0.700 0.644
tTau Demographics, PGRS and plasma tau 0.653 0.608 0.689 0.649
A Demographics only 0.709 0.787 0.530 0.658
A Demographics and PGRS 0.697 0.769 0.532 0.650
A Demographics and plasma tau 0.743 0.813 0.582 0.697
A Demographics, PGRS and plasma tau 0.725 0.813 0.523 0.668
Total CSF burden Demographics only 0.772 0.742 0.816 0.779
Total CSF burden Demographics and PGRS 0.763 0.735 0.804 0.769
Total CSF burden Demographics and plasma tau 0.758 0.765 0.748 0.756
Total CSF burden Demographics, PGRS and plasma tau 0.772 0.780 0.756 0.768
AUC ROC, area under the receiver operating curve; PGRS, polygenic risk score.
and plasma tau, did not improve model accuracy in
the majority of cases.
Firstly, this could be explained by the PGRS being
trained on a case/control endpoint. As individuals can
often be misdiagnosed with AD the case/control phe-
notype can be misleading. GWAS are beginning to be
large enough to detect risk SNPs associated with A
and tau. When sample sizes in these studies increase
further they should be used to train PGRS. Intuitively,
they may achieve improved predictive ability than
models based on a case/control PGRS. Furthermore,
due to the relatively small sample size of this study,
the PGRS only utilizes common variation excluding
loci such as TREM2. As larger studies become avail-
able the inclusion of such rarer variants in genetic risk
scoring should be considered.
In the sub-study, it is interesting that plasma tau is
no more predictive of CSF tau than age, gender, and
APOE genotype. Furthermore, plasma tau achieves a
higher accuracy when modeling CSF A. The lack
of ability to predict CSF tau indicates the need for
further assay development to detect still more sen-
sitive measurements. Furthermore, research into the
permeability of the blood-brain barrier will help the-
orize as to how much pathology signal from the brain
and CSF is likely to be seen in blood.
This study has shown the importance of replication
in independent datasets; models that perform well in
training data often do not replicate. It is particularly
important to test replicability when standardized pro-
tocols for assays do not exist [34]. For example, this
analysis highlights the difference between EDAR,
DESCRIPA, and ADNI in the assays and cut-offs
used to define high and low pathology burden. The
CSF A cut-off for high/ low burden ranges between
192 pg/ml and 550 pg/ml. Efforts are being made to
standardize such metrics for future research [35, 36].
It is important to point out the limitations of
this study. Firstly, there are differences in sam-
ple collection methods, assays and data processing
pipelines between ADNI 1, ADNI 2, EDAR, and
DESCRIPA. In particular, the GWAS platforms used
differ between the studies. The models in this study
are trained in ADNI 1, which uses a slightly older Illu-
mina chip (Human610-Quad) than ADNI 2, EDAR,
and DESCRIPA. Although this means that the data
from the other cohorts may not be fully utilized, it
is unlikely to cause a lack of replicability. However,
it is possible that some replicability is lost due to
differences in sample collection methods and data
processing. Furthermore, the use of the older SNP
chip (Human610-Quad in ADNI 1) may have lead
to reduced SNP content and sub-optimal imputation
within the ADNI 1 cohort. It is also of note that the
ADNI study was included in IGAP, effect sizes from
which were used to create the PGRS. We believe
that the benefit of a larger sample size for train-
ing outweighs any negative impact. Despite the use
of well-characterized cohorts in this study, we must
point out that the sample size considered is still rela-
tively small. In future work, this could be addressed
by the use of longitudinal aging studies instead of the
case/control cohort studies used here.
Finally, we have shown that the multi-modal
approach used in the sub-study investigating plasma
tau, did not improve predictive ability above the basic
model. We used a simple additive model and more
complex methods such as OmicKriging may be use-
ful in this setting [37]. Furthermore, the standard for
measuring AD pathology, in particular A, is through
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PET imaging. Generally, PET imaging and CSF mea-
surements are used interchangeably but any results
should be replicated using imaging based outcomes.
In combination with a pathological endpoint more
closely related to an AD phenotype, such as the total
CSF burden used here, the suggestions presented in
this discussion could improve the predictive ability
of proposed markers of A and tau.
CONCLUSIONS
This study has used data from the EDAR,
DESCRIPA, and ADNI cohorts to investigate blood
markers of A and tau. We see that a case/control
PGRS is no more predictive of pathology than age,
gender, and APOE genotype. A sub-study shows that
model accuracy is not improved by the addition of
plasma tau measurements. These results emphasize
that the search for predictive factors of A and tau,
above and beyond demographic and APOE informa-
tion, is still ongoing. Better understanding of AD risk
alleles, development of more sensitive assays, and
studies of larger sample size are three avenues that
may provide such factors. However, the clinical util-
ity of possible predictors of brain A and tau must
also be investigated.
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